View Older Stories
-
Apogee Therapeutics board to lose two directors in May
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
BTIG on Apogee Therapeutics Inc (APGE): data continues to support BIC positioning
-
Apogee Therapeutics Inc (APGE) PT Raised to $110 at Mizuho
-
Apogee Therapeutics Inc (APGE) PT Raised to $160 at Guggenheim
-
Apogee Therapeutics Inc (APGE) PT Raised to $130 at Canaccord
-
Truist on Apogee Therapeutics Inc (APGE) amid 22pct Gain: ' we see ~10–20% upside for the shares today'
-
Mizuho on Apogee Therapeutics Inc (APGE): data shows potential 'best-in-indication biologic efficacy and convenience'
-
Apogee Therapeutics Inc (APGE) PT Raised to $131 at BofA Securities
-
Apogee Therapeutics Inc (APGE) PT Raised to $100 at Jefferies
-
Stifel on Apogee Therapeutics Inc (APGE): 'data further derisks Zumilokibart's TPP,' approval path
-
Truist Securities Starts Apogee Therapeutics Inc (APGE) at Hold
-
Citi Opens Catalyst Watch on Apogee Therapeutics Inc (APGE)
-
Apogee Therapeutics Inc (APGE) PT Lowered to $82 at RBC Capital
-
Apogee Therapeutics Inc (APGE) PT Raised to $95 at Wedbush
-
Apogee Therapeutics Inc (APGE) PT Lowered to $95 at Jefferies
-
RBC Capital Downgrades Apogee Therapeutics Inc (APGE) to Sector Perform
-
Stifel: 'REGN Announcements Validate APGE Thesis'
-
Apogee Therapeutics (APGE) call put ratio 3 calls to 1 put
-
Apogee Therapeutics Inc (APGE) PT Raised to $116 at Craig-Hallum
-
UBS Starts Apogee Therapeutics Inc (APGE) at Buy
-
Wolfe Research Starts Apogee Therapeutics Inc (APGE) at Peerperform
-
RBC on Apogee Therapeutics Inc (APGE): 'we remain bullish on APGE's outlook'
-
Apogee Therapeutics Inc (APGE) PT Raised to $137 at BTIG
-
BTIG on Apogee (APGE): 'DUPLEX-AD's Failure is Likely a Clearing Event for APG279 and APG777 in Atopic Dermatitis'
-
Here's the list of top biotech stocks to own for 2026
-
Stephens Starts Apogee Therapeutics Inc (APGE) at Overweight
-
Deutsche Bank Starts Apogee Therapeutics Inc (APGE) at Buy
-
Where can biotech stocks go from here? RBC answers
-
Craig-Hallum Starts Apogee Therapeutics Inc (APGE) at Buy
-
Apogee Therapeutics Inc (APGE) PT Raised at RBC Capital on Pipeline Potential
-
Mizuho Starts Apogee Therapeutics Inc (APGE) at Outperform
-
Apogee Therapeutics Inc (APGE) PT Lowered to $82 at BofA Securities
-
After-hours movers: Costco, AZZ, Richardson Electronics, Apogee
-
Apogee Therapeutics (APGE) 2400 contracts of April 50 calls trade
-
RBC Capital Starts Apogee Therapeutics Inc (APGE) at Outperform
-
Goldman Sachs Reiterates Early-Stage Biotech Rating on Apogee Therapeutics Inc (APGE)
-
Stifel Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
-
Apogee Therapeutics Inc (APGE) PT Raised to $96 at Jefferies
-
Canaccord Genuity Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
-
Citi Defending Apogee Therapeutics Inc (APGE): 'we are buyers on weakness'
-
Apogee Therapeutics (APGE) reports positive atopic dermatitis trial results for APG777
-
Guggenheim Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
-
Stifel Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
-
TD Cowen: 'Own Apogee Therapeutics Inc (APGE)'
-
Stifel Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
-
Canaccord Genuity Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
-
BTIG Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
-
Apogee Therapeutics (APGE) Announces Positive Interim Results from the Phase 1b Trial of APG808
-
Stifel Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)

